Drug intelligence / Profile preview

Picozyme

Development stage: Unknown
Lead developer: PICO Entech
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Oral

Overview

Picozyme is an enzyme-based consumer health supplement developed by PICO Entech. It is part of the company's portfolio of functional products utilizing proprietary ALDH (Aldehyde Dehydrogenase) enzyme technology and ARC (Aldehyde-Reducing Complex) Platform Science. The product is designed to support metabolic health by facilitating the breakdown of aldehydes, which are toxic metabolic byproducts. While PICO Entech conducts research into therapeutic applications of ALDH technology for conditions such as Parkinson's disease, liver dysfunction, and diabetes, Picozyme is currently marketed as a commercial health supplement and functional food product.

Brand names: Picozyme

Targets

ALDH1A1 (Aldehyde dehydrogenase 1 family member A1)

Beyond the preview

Go deeper on Picozyme.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Picozyme.

Explore the full profile